Monthly
US$200
Billed every month
Metronidazole Suppositories(甲硝唑栓)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 applicationNo longer listed under review: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders0View records ↓
Under-review filings1View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers25View records ↓
API companies with A status23View records ↓
Chemical-drug catalogue
Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 25 distinct approval numbers and 18 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 北京双吉制药有限公司 | 国药准字H11022305 | 0.5g | Category A (甲) | XG01AFJ070D003010100176 | NHSA |
| 国药集团工业有限公司 | 国药准字H31020395 | 0.5g | Category A (甲) | XG01AFJ070D003010100814 | NHSA |
| 天津金耀药业有限公司 | 国药准字H12020699 | 1g | Category A (甲) | XG01AFJ070D003010100952 | NHSA |
| 湖北东信药业有限公司 | 国药准字H42021784 | 0.5g | Category A (甲) | XG01AFJ070D003010101792 | NHSA |
| 湖北潜江制药股份有限公司 | 国药准字H42021261 | 0.5g | Category A (甲) | XG01AFJ070D003010101853 | NHSA |
| 马应龙药业集团股份有限公司 | 国药准字H42020376 | 0.5g | Category A (甲) | XG01AFJ070D003010101954 | NHSA |
| 湖北省宏源药业科技股份有限公司 | 国药准字H42021747 | 0.5g | Category A (甲) | XG01AFJ070D003010101974 | NHSA |
| 成都第一制药有限公司 | 国药准字H51023193 | 0.5g | Category A (甲) | XG01AFJ070D003010102080 | NHSA |
| 山西双雁药业有限公司 | 国药准字H14020743 | 0.5g | Category A (甲) | XG01AFJ070D003010102954 | NHSA |
| 黑龙江省富东制药有限公司 | 国药准字H23020677 | 0.5g | Category A (甲) | XG01AFJ070D003010103761 | NHSA |
| 黑龙江省济仁药业有限公司 | 国药准字H20058324 | 0.5g | Category A (甲) | XG01AFJ070D003010103767 | NHSA |
| 威海华新药业集团有限公司 | 国药准字H37021380 | 0.5g | Category A (甲) | XG01AFJ070D003010104217 | NHSA |
| 安徽天洋药业有限公司 | 国药准字H20065914 | 每枚0.5g | Category A (甲) | XG01AFJ070D003010104350 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H33022186 | 0.5g | Category A (甲) | XG01AFJ070D003010104693 | NHSA |
| 明顺医疗投资(深圳)有限公司 | 国药准字H43021486 | 0.5g | Category A (甲) | XG01AFJ070D003010104920 | NHSA |
| 黑龙江嘉悦泽生物制药有限公司 | 国药准字H45021412 | 0.5g | Category A (甲) | XG01AFJ070D003010105095 | NHSA |
| 昆明梓橦宫全新生物制药有限公司 | 国药准字H53021276 | 0.5g | Category A (甲) | XG01AFJ070D003010105599 | NHSA |
| 云南白药集团股份有限公司 | 国药准字H53021481 | 0.5g | Category A (甲) | XG01AFJ070D003010105612 | NHSA |
| 黑龙江省富东制药有限公司 | 国药准字H23020677 | 0.5g | Category A (甲) | XG01AFJ070D003010203761 | NHSA |
| 黑龙江省济仁药业有限公司 | 国药准字H20058324 | 0.5g | Category A (甲) | XG01AFJ070D003010203767 | NHSA |
| 威海华新药业集团有限公司 | 国药准字H37021380 | 0.5g | Category A (甲) | XG01AFJ070D003010204217 | NHSA |
| 明顺医疗投资(深圳)有限公司 | 国药准字H43021486 | 0.5g | Category A (甲) | XG01AFJ070D003010204920 | NHSA |
| 黑龙江嘉悦泽生物制药有限公司 | 国药准字H45021412 | 0.5g | Category A (甲) | XG01AFJ070D003010205095 | NHSA |
| 黑龙江省富东制药有限公司 | 国药准字H23020677 | 0.5g | Category A (甲) | XG01AFJ070D003010303761 | NHSA |
| 黑龙江省济仁药业有限公司 | 国药准字H20058324 | 0.5g | Category A (甲) | XG01AFJ070D003010303767 | NHSA |
| 明顺医疗投资(深圳)有限公司 | 国药准字H43021486 | 0.5g | Category A (甲) | XG01AFJ070D003010304920 | NHSA |
| 黑龙江嘉悦泽生物制药有限公司 | 国药准字H45021412 | 0.5g | Category A (甲) | XG01AFJ070D003010305095 | NHSA |
| 黑龙江嘉悦泽生物制药有限公司 | 国药准字H45021412 | 0.5g | Category A (甲) | XG01AFJ070D003010405095 | NHSA |
| 北京双吉制药有限公司 | 国药准字H11022304 | 0.25g | Category A (甲) | XG01AFJ070D003020100176 | NHSA |
| 湖北省宏源药业科技股份有限公司 | 国药准字H42021747 | 0.5g | Category A (甲) | XG01AFJ070D003020101974 | NHSA |
| 成都第一制药有限公司 | 国药准字H51023192 | 1g | Category A (甲) | XG01AFJ070D003020102080 | NHSA |
| 黑龙江省富东制药有限公司 | 国药准字H23020677 | 0.5g | Category A (甲) | XG01AFJ070D003020103761 | NHSA |
| 明顺医疗投资(深圳)有限公司 | 国药准字H43021485 | 1.0g | Category A (甲) | XG01AFJ070D003020104920 | NHSA |
| 昆明梓橦宫全新生物制药有限公司 | 国药准字H53021275 | 1.0g | Category A (甲) | XG01AFJ070D003020105599 | NHSA |
| 云南白药集团股份有限公司 | 国药准字H53021482 | 1g | Category A (甲) | XG01AFJ070D003020105612 | NHSA |
| 明顺医疗投资(深圳)有限公司 | 国药准字H43021485 | 1.0g | Category A (甲) | XG01AFJ070D003020204920 | NHSA |
| 明顺医疗投资(深圳)有限公司 | 国药准字H43021485 | 1.0g | Category A (甲) | XG01AFJ070D003020304920 | NHSA |
| 黑龙江省富东制药有限公司 | 国药准字H23020677 | 0.5g | Category A (甲) | XG01AFJ070D003020403761 | NHSA |
| 明顺医疗投资(深圳)有限公司 | 国药准字H43021485 | 1.0g | Category A (甲) | XG01AFJ070D003020404920 | NHSA |
| 北京双吉制药有限公司 | 国药准字H11021389 | 0.5g | Category A (甲) | XG01AFJ070D003030100176 | NHSA |
| 北京双吉制药有限公司 | 国药准字H11021389 | 0.5g | Category A (甲) | XG01AFJ070D003030200176 | NHSA |
| 北京双吉制药有限公司 | 国药准字H11021388 | 1g | Category A (甲) | XG01AFJ070D003040100176 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 1 filings and 1 distinct first applicants.
Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 湖北东信药业有限公司 | CYHB2601150 | Supplement | 2026/06/17 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
API registrations
Non-component matches: 23 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 甲硝唑 | 济南明鑫制药股份有限公司 | Y20240000004 | A | Exact ingredient | 2025/08/01 | CDE |
| 甲硝唑 | 信合援生制药股份有限公司 | Y20220000637 | A | Exact ingredient | 2026/03/03 | CDE |
| 甲硝唑 | AARTI DRUGS LIMITED | Y20210000013 | A | Exact ingredient | 2023/04/07 | CDE |
| 甲硝唑 | 广西金兴制药有限责任公司 | Y20209990025 | A | Exact ingredient | 2024/10/09 | CDE |
| 甲硝唑 | 黄冈银河阿迪药业有限公司 | Y20190009773 | A | Exact ingredient | 2026/01/20 | CDE |
| 甲硝唑 | 湖北省宏源药业科技股份有限公司 | Y20190009755 | A | Exact ingredient | — | CDE |
| 甲硝唑 | 山西同济药业有限公司 | Y20190008615 | A | Exact ingredient | 2026/08/05 | CDE |
| 甲硝唑 | 武汉武药制药有限公司 | Y20190008552 | A | Exact ingredient | 2025/06/12 | CDE |
| 甲硝唑 | 青岛首和金海制药有限公司 | Y20190005405 | A | Exact ingredient | 2024/01/12 | CDE |
| 甲硝唑 | 江苏吉贝尔药业股份有限公司 | Y20190004966 | A | Exact ingredient | 2025/05/07 | CDE |
| 甲硝唑 | 桂林南药股份有限公司 | Y20190004293 | A | Exact ingredient | 2025/01/18 | CDE |
| 甲硝唑 | 东港市宏达制药有限公司 | Y20190004198 | A | Exact ingredient | 2025/04/15 | CDE |
| 甲硝唑 | 广东香雪药业有限公司 | Y20190003967 | A | Exact ingredient | — | CDE |
| 甲硝唑 | 锦州九泰药业有限责任公司 | Y20190003819 | A | Exact ingredient | 2025/05/13 | CDE |
| 甲硝唑 | 丹东医创药业有限责任公司 | Y20190003816 | A | Exact ingredient | 2025/06/07 | CDE |
| 甲硝唑 | 万邦德制药集团有限公司 | Y20190003607 | A | Exact ingredient | 2024/11/02 | CDE |
| 甲硝唑 | 苏州弘森药业股份有限公司 | Y20190003215 | A | Exact ingredient | 2025/06/06 | CDE |
| 甲硝唑 | 宜昌东阳光长江药业股份有限公司 | Y20190003169 | A | Exact ingredient | — | CDE |
| 甲硝唑 | 河北广祥制药有限公司 | Y20190002958 | A | Exact ingredient | 2024/07/23 | CDE |
| 甲硝唑 | 山西仟源医药集团股份有限公司 | Y20190002879 | A | Exact ingredient | — | CDE |
| 甲硝唑 | 黄冈赛康药业有限公司 | Y20190002607 | A | Exact ingredient | 2026/05/20 | CDE |
| 甲硝唑 | 恒诚制药集团淮南有限公司 | Y20190002432 | A | Exact ingredient | 2025/01/14 | CDE |
| 甲硝唑 | 广东华润顺峰药业有限公司 | Y20190001518 | A | Exact ingredient | 2024/08/15 | CDE |
| 甲硝唑 | 黄冈银河阿迪药业有限公司 | Y20170001867 | A | Exact ingredient | 2024/10/17 | CDE |
| 甲硝唑 | 湖北省宏源药业科技股份有限公司 | Y20170001945 | A | Exact ingredient | 2026/02/05 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/29No longer listed under review
江苏瑜兴医药科技有限公司
CYHL2600088
Fact date: 2026/10/29 · Site observation date: 2026/10/29
Accepted: 2026/08/19
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/08/19Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Metronidazole Suppositories
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy